Please login to the form below

Not currently logged in
Email:
Password:

follicular lymphoma

This page shows the latest follicular lymphoma news and features for those working in and with pharma, biotech and healthcare.

Another R&D flop for Incyte, but Jakafi keeps delivering

Another R&D flop for Incyte, but Jakafi keeps delivering

Meanwhile, Incyte was quick to point out that the failure of PI3K delta inhibitor INCB50465 in a form of NHL called diffuse large B cell lymphoma (DLBCL) does not affect phase ... II testing of the drug in other indications, including follicular lymphoma,

Latest news

  • NHS chief pledges CAR-T support, but asks for pricing restraint NHS chief pledges CAR-T support, but asks for pricing restraint

    Kite’s CAR-T Yescarta (axicabtagene ciloleucel) was the first to be submitted for approval in Europe and is being reviewed by the EMA for diffuse large B-cell lymphoma (DLBCL), ... primary mediastinal B-cell lymphoma (PMBCL) and transformed follicular

  • NICE backs Roche’s Gazyvaro after initial rejection NICE backs Roche’s Gazyvaro after initial rejection

    The UK’s National Institute for Health and Care Excellence (NICE) has recommended Roche’s Gazyvaro as a first-line treatment for lymphoma patients, reversing its earlier stance on the drug. ... Last September the cost-effectiveness watchdog turned

  • Novartis files CAR-T therapy CTL109 in Europe Novartis files CAR-T therapy CTL109 in Europe

    as follow-up indication diffuse large B-cell lymphoma (DLBCL) which it submitted to the FDA last month. ... Kite was the first to file its new therapy in Europe, seeking approval in August for DLBCL, transformed follicular lymphoma (TFL), and primary

  • Roche's Actemra/RoActemra receives new European approval Roche's Actemra/RoActemra receives new European approval

    Gazyvaro approved for advanced follicular lymphoma. Meanwhile, the European Commission has also licensed Roche’s Gazyvaro (obinutuzumab) for patients with previously untreated advanced follicular lymphoma. ... with follicular lymphoma who did not

  • Bayer bags speedy US approval for lymphoma drug Aliqopa Bayer bags speedy US approval for lymphoma drug Aliqopa

    The FDA has approved Bayer's PI3K inhibitor Aliqopa, setting up a market showdown with Gilead Sciences' Zydelig in follicular lymphoma. ... Richard Pazdur, director of the FDA's Office of Haematology and Oncology Products, said: "For patients with

More from news
Approximately 2 fully matching, plus 47 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics